DK3233066T3 - Orlistat- og acarbosepræparat med modificeret frigivelse til behand-ling af obesitas og relaterede metaboliske lidelser - Google Patents

Orlistat- og acarbosepræparat med modificeret frigivelse til behand-ling af obesitas og relaterede metaboliske lidelser Download PDF

Info

Publication number
DK3233066T3
DK3233066T3 DK15813822.2T DK15813822T DK3233066T3 DK 3233066 T3 DK3233066 T3 DK 3233066T3 DK 15813822 T DK15813822 T DK 15813822T DK 3233066 T3 DK3233066 T3 DK 3233066T3
Authority
DK
Denmark
Prior art keywords
obesitas
orlistat
treatment
modified release
metabolic disorders
Prior art date
Application number
DK15813822.2T
Other languages
English (en)
Inventor
Göran Alderborn
Anders Forslund
Ulf Holmbäck
Hans Lennernäs
Jan Stefan Persson Grudén
Original Assignee
Empros Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52146175&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3233066(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Empros Pharma Ab filed Critical Empros Pharma Ab
Application granted granted Critical
Publication of DK3233066T3 publication Critical patent/DK3233066T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Inorganic Chemistry (AREA)
DK15813822.2T 2014-12-17 2015-12-17 Orlistat- og acarbosepræparat med modificeret frigivelse til behand-ling af obesitas og relaterede metaboliske lidelser DK3233066T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14198468 2014-12-17
PCT/EP2015/080265 WO2016097170A1 (en) 2014-12-17 2015-12-17 A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders

Publications (1)

Publication Number Publication Date
DK3233066T3 true DK3233066T3 (da) 2022-01-10

Family

ID=52146175

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15813822.2T DK3233066T3 (da) 2014-12-17 2015-12-17 Orlistat- og acarbosepræparat med modificeret frigivelse til behand-ling af obesitas og relaterede metaboliske lidelser

Country Status (28)

Country Link
US (3) US10561617B2 (da)
EP (3) EP4364743A3 (da)
JP (1) JP6607955B2 (da)
KR (2) KR102094631B1 (da)
CN (1) CN107405309B (da)
AU (1) AU2015367422B2 (da)
BR (1) BR112017012714B1 (da)
CA (1) CA2970991C (da)
CL (1) CL2017001574A1 (da)
CO (1) CO2017005834A2 (da)
DK (1) DK3233066T3 (da)
EA (1) EA033448B1 (da)
EC (1) ECSP17035750A (da)
ES (1) ES2901122T3 (da)
HU (1) HUE057093T2 (da)
IL (1) IL252865B2 (da)
MX (3) MX2017007493A (da)
MY (1) MY195038A (da)
NZ (1) NZ732241A (da)
PE (1) PE20171243A1 (da)
PH (1) PH12017550023A1 (da)
PL (1) PL3233066T3 (da)
SA (1) SA517381713B1 (da)
SG (1) SG11201704470PA (da)
SI (1) SI3233066T1 (da)
UA (1) UA122403C2 (da)
WO (1) WO2016097170A1 (da)
ZA (1) ZA201704590B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2970991C (en) 2014-12-17 2021-08-03 Goran Alderborn A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
EP3470065B1 (en) * 2016-06-09 2026-02-11 Bussan Animal Health Co., Ltd. Sustained-release preparation composition for animals
GB201803363D0 (en) 2018-03-01 2018-04-18 Sigrid Therapeutics Ab New materials and uses thereof
WO2020227437A1 (en) * 2019-05-06 2020-11-12 Axial Biotherapeutics, Inc. Sustained release solid dosage forms for modulating the colonic microbiome
KR102508141B1 (ko) * 2019-07-01 2023-03-10 주식회사 연세대학교 바이오헬스기술지주회사 하이드로겔 및 egfr 리간드를 유효성분으로 포함하는 당 배출용 조성물
ES2975442T3 (es) * 2019-12-11 2024-07-05 Evonik Operations Gmbh Forma farmacéutica para su uso en el tratamiento o la prevención de una enfermedad
CN114828833A (zh) 2019-12-11 2022-07-29 赢创运营有限公司 包含碱剂和肠溶包衣层的剂型
CN111297826B (zh) * 2020-04-20 2021-08-03 鲁南制药集团股份有限公司 一种稳定的奥利司他胶囊及其制备方法
WO2022154687A1 (ru) * 2021-01-14 2022-07-21 Общество C Ограниченной Ответственностью "Новамедика" Фармацевтическая композиция, включающая эзомепразол
WO2022243525A1 (en) 2021-05-21 2022-11-24 Empros Pharma Ab Synergistic effects on weight loss, improved quality of life and gastro-intestinal side effects with a composition of orlistat and acarbose
WO2022243528A1 (en) 2021-05-21 2022-11-24 Empros Pharma Ab Use of a composition comprising orlistat and acarbose to obtain a sustained weight loss
WO2022243534A1 (en) 2021-05-21 2022-11-24 Empros Pharma Ab Reduced rebound effects in subjects treated for overweight or obesity
EP4392044A4 (en) * 2021-09-09 2025-01-22 Junion Labs Pte. Ltd. SUPERABSORBENT HYDROGELS WITH LIPASE INHIBITOR
WO2024102902A1 (en) * 2022-11-10 2024-05-16 Temple University-Of The Commonwealth System Of Higher Education Methods of treating or preventing liver diseases or disorders
CN117502631A (zh) * 2023-12-11 2024-02-06 浙江华康药业股份有限公司 调节胃肠激素的甜味剂组合物及其制备方法
WO2025207711A1 (en) * 2024-03-27 2025-10-02 Mayo Foundation For Medical Education And Research Lipase inhibitor compositions and methods for treating diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8101930A (nl) 1981-04-21 1982-11-16 Philips Nv Contactinrichting voor een meeraderige kabel.
CA2128044C (en) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
JP2001523704A (ja) * 1997-11-25 2001-11-27 バイエル・アクチエンゲゼルシヤフト α−グルコシダーゼ阻害剤を含んで成る持続放出性製剤
DE19802700A1 (de) * 1998-01-24 1999-07-29 Bayer Ag Verfahren zur Herstellung einer im Mund schnell zerfallenden Arzneiform, die als Wirkstoff Acarbose enthält
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
WO2000028989A1 (en) * 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US6419954B1 (en) * 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
US6849609B2 (en) * 2001-04-10 2005-02-01 James U. Morrison Method and composition for controlled release acarbose formulations
WO2003009840A1 (en) * 2001-07-24 2003-02-06 Lonza Ag Composition comprising at least one lipase inhibitor and carnitine
CN1296050C (zh) * 2003-12-10 2007-01-24 浙江海正药业股份有限公司 阿卡波糖肠溶片及制备方法
US20060229261A1 (en) * 2005-04-12 2006-10-12 John Devane Acarbose methods and formulations for treating chronic constipation
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
EP1872777A1 (en) * 2006-06-27 2008-01-02 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising tetrahydrolipstatin
KR100857411B1 (ko) * 2006-07-21 2008-09-08 한올제약주식회사 리파아제 저해제의 경구 투여용 방출조절 약학 제제 및이의 제조 방법
US8110186B2 (en) * 2006-09-18 2012-02-07 Chelatexx, LLC Method to maintain the efficacy of orlistat
CN100464754C (zh) * 2007-03-12 2009-03-04 杭州中美华东制药有限公司 阿卡波糖药物组合物及其制备方法
TW200841876A (en) * 2007-04-18 2008-11-01 Anchen Pharmaceuticals Taiwan Inc Pharmaceutical composition containing orlistat
EA201070378A1 (ru) 2007-09-17 2010-08-30 Др. Редди`С Лабораторис Лтд. Фармацевтические составы орлистата
WO2010065491A2 (en) * 2008-12-01 2010-06-10 Carolus Therapeutics, Inc. Methods of treating inflammatory disorders
PH12012502139A1 (en) * 2010-04-27 2022-03-21 Bayer Ip Gmbh Orally disintegrating tablet containing acarbose
AU2011275881B2 (en) * 2010-07-05 2014-11-06 Jagotec Ag Dosage form
TR201100148A2 (tr) * 2011-01-06 2012-07-23 Bi̇lgi̇ç Mahmut Stabil akarboz förmülasyonları.
CN102872062A (zh) 2011-07-13 2013-01-16 鲁南制药集团股份有限公司 一种治疗或预防肥胖症以及代谢综合症的药物组合物
CA2970991C (en) 2014-12-17 2021-08-03 Goran Alderborn A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders

Also Published As

Publication number Publication date
UA122403C2 (uk) 2020-11-10
IL252865B (en) 2022-11-01
CN107405309B (zh) 2019-04-16
MX2019001376A (es) 2019-05-30
CL2017001574A1 (es) 2018-01-26
AU2015367422B2 (en) 2017-11-02
CN107405309A (zh) 2017-11-28
EA201791348A1 (ru) 2017-09-29
NZ732241A (en) 2019-01-25
EP4364743A3 (en) 2024-08-28
MX2021003905A (es) 2021-09-30
SG11201704470PA (en) 2017-07-28
KR20190004816A (ko) 2019-01-14
EP3233066A1 (en) 2017-10-25
US12629340B2 (en) 2026-05-19
BR112017012714A2 (pt) 2018-03-13
CA2970991C (en) 2021-08-03
JP6607955B2 (ja) 2019-11-20
CA2970991A1 (en) 2016-06-23
CO2017005834A2 (es) 2017-11-30
MY195038A (en) 2023-01-04
EP3943076A3 (en) 2022-04-13
PL3233066T3 (pl) 2022-02-14
HUE057093T2 (hu) 2022-04-28
ES2901122T3 (es) 2022-03-21
EP3943076A2 (en) 2022-01-26
MX382196B (es) 2025-03-13
WO2016097170A1 (en) 2016-06-23
ZA201704590B (en) 2022-03-30
AU2015367422A1 (en) 2017-06-15
JP2018501310A (ja) 2018-01-18
PH12017550023A1 (en) 2017-10-18
SA517381713B1 (ar) 2022-03-17
US11975105B2 (en) 2024-05-07
KR102094631B1 (ko) 2020-03-27
SI3233066T1 (sl) 2022-02-28
US10561617B2 (en) 2020-02-18
KR20170090505A (ko) 2017-08-07
EP3233066B1 (en) 2021-11-10
US20170360715A1 (en) 2017-12-21
ECSP17035750A (es) 2017-08-31
KR101937069B1 (ko) 2019-04-03
IL252865B2 (en) 2023-03-01
PE20171243A1 (es) 2017-08-24
EA033448B1 (ru) 2019-10-31
US20200230063A1 (en) 2020-07-23
BR112017012714B1 (pt) 2023-09-26
US20240342096A1 (en) 2024-10-17
EP4364743A2 (en) 2024-05-08
IL252865A0 (en) 2017-08-31
MX2017007493A (es) 2018-01-26

Similar Documents

Publication Publication Date Title
ZA201900278B (en) Variant adeno-associated viruses and methods of using
DK3212226T3 (da) Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser
IL249292A0 (en) Methods and devices for treating pulmonary edema
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3492632T3 (da) Metoder til behandling af lithiumholdige materialer
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK3851537T5 (da) Behandling af hyperbilirubinæmi
EP4212536C0 (en) BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
ZA201704590B (en) A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
DK3102555T3 (da) Sammensætninger af forbindelser og anvendelser deraf
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3331879T3 (da) Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
DK3099298T3 (da) Kombinationsterapier med zidovudin til behandling af mikrobielle infektioner
DK3178324T3 (da) Mikrobicid og fremgangsmåde til fremstilling af samme
DK3142664T3 (da) Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
BR112016022976A2 (pt) Métodos para o tratamento de hcv
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose
DK3192524T3 (da) Hgf præparat egnet til behandling af neurologiske lidelser
DK3209295T4 (da) Fremgangsmåder til behandling af øjenlidelser